Our mission is to orchestrate a cure for muscular dystrophies caused by dysferlin protein deficiency. These are collectively termed dysferlinopathy, and clinically are referred to as LGMD2B, LGMDR2, or Miyoshi Myopathy 1 (MM1). Our non-traditional funding model strategically funds and partners with scientific researchers, institutions, and companies.  Additionally, we provide logistical support in drug development and clinical trials and have built a strong patient support and advocacy platform.

Jain Foundation Inc

Org chart

Teams

Offices